Skip to content

Axogen AXGN Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Baxter International logo
Baxter InternationalBAX
IAR
Integra LifeSciencesIART
Enovis logo
EnovisENOV
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$61.5M+26.6%
Gross profit$46.2M+32.2%
Operating income-$2.8M-70.5%
Net income-$19.6M-411%
EPS (diluted)-$0.38-375%

Balance sheet

See full
Cash & equivalents$84.7M+251%
Total debt$20.6M-69.8%
Total equity$244.8M+132%
Total assets$289.5M+47.6%

Cash flow

See full
Operating cash flow$1.6M+112%
CapEx$2.8M+989%
Free cash flow-$1.2M+90.9%

Valuation

See full
Market cap$2.26B+110%
Enterprise value$2.2B+91.4%
P/S9.5×+4.0×

Profitability

See full
Gross margin75%+0.8pp
Operating margin-3.8%
Net margin-13.2%-22.8pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18%-70.5pp
Debt / equity0.1×-0.6×
Current ratio7.1×+2.8×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Axogen’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axogen's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axogen's common stock, shares authorized (in shares)?
Axogen (AXGN) reported common stock, shares authorized (in shares) of $100M in Q1 2026.
How has Axogen's common stock, shares authorized (in shares) changed year-over-year?
Axogen's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $100M to $100M.
What is the long-term trend for Axogen's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Axogen's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $100M to $100M.